サマリー

欧州の医療用大麻市場は、2023年の26億2,567万米ドルから2031年には246億4,606万米ドルに達し、2023年から2030年の予測期間中に年平均成長率33.6％で成長すると予測
市場細分化：
欧州医療用大麻市場：製品別（オイル、乾燥医療用大麻、医療用大麻カプセル、ホールフラワー、グラウンドフラワー、VAPEペン、乾燥医療用大麻、クリーム＆保湿剤、その他）、供給源別（合成および天然）、種（カンナビス・インディカ、サティバ、ハイブリッド）、誘導体（カンナビジオール（CBD）、テトラヒドロカンナビノール（THC）、その他）、（用途（疼痛管理、不安、筋痙攣、吐き気、食欲不振、がん、関節炎、アルツハイマー病／偏頭痛、てんかん、うつ病および睡眠障害、多発性硬化症、自閉症、精神疾患、気分の高揚、その他）、投与経路（経口剤およびカプセル、喫煙、気化器、局所剤、その他）、エンドユーザー（製薬業界、研究開発センター、在宅ケア設定、病院およびリハビリセンター、その他）、流通チャネル（B2BおよびB2C）、国（ドイツ、U.K.,国（ドイツ、英国、オランダ、スイス、フランス、ロシア、スペイン、ベルギー、ギリシャ、ルクセンブルグ、その他ヨーロッパ）産業動向と2031年までの予測
欧州医療用大麻市場ダイナミクスの概要

推進要因
- 大麻の使用を必要とする疾患の発生率の上昇

抑制要因

- 医療用大麻の使用に関する倫理的問題
機会

- 医療用大麻の薬物使用の増加


市場プレイヤー

欧州の医療用大麻市場で事業を展開する主なプレーヤーは以下の通りである：

- ティルレイ
- メディファーム・ラボ
- アルテア社
- ファーマヘンプ
- オーロラ・カンナビス
- キャノピー・グロース・コーポレーション
- ジャズファーマシューティカルズ
- エコジェン・バイオサイエンス
- グラス＆カンパニー
- カンナレイ
- サニティ・グループGmbH
- 株式会社ヘクソ

ページTOPに戻る

目次

TABLE OF CONTENTS
1 INTRODUCTION 31
1.1 OBJECTIVES OF THE STUDY 31
1.2 MARKET DEFINITION 31
1.3 OVERVIEW OF THE EUROPE MEDICAL CANNABIS MARKET 31
1.4 LIMITATIONS 33
1.5 MARKETS COVERED 34
2 MARKET SEGMENTATION 38
2.1 MARKETS COVERED 38
2.2 GEOGRAPHICAL SCOPE 39
2.3 YEARS CONSIDERED FOR THE STUDY 39
2.4 CURRENCY AND PRICING 39
2.5 DBMR TRIPOD DATA VALIDATION MODEL 40
2.6 MULTIVARIATE MODELLING 43
2.7 PRODUCT LIFELINE CURVE 43
2.8 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS 44
2.9 DBMR MARKET POSITION GRID 45
2.10 MARKET END USER COVERAGE GRID 46
2.11 VENDOR SHARE ANALYSIS 47
2.12 SECONDARY SOURCES 48
2.13 ASSUMPTIONS 48
3 EXECUTIVE SUMMARY 49
4 PREMIUM INSIGHTS 52
4.1 PORTER’S FIVE FORCES 53
4.2 PESTEL ANALYSIS 54
4.3 EUROPE MEDICAL CANNABIS MARKET: AVAILABLE PRODUCTS WITH PRICES 55
5 EUROPE MEDICAL CANNABIS MARKET: REGULATIONS 57
6 MARKET OVERVIEW 63
6.1 DRIVERS 65
6.1.1 RISE IN GERIATRIC POPULATION 65
6.1.2 RISE IN INCIDENCE OF DISEASES THAT REQUIRE THE USE OF CANNABIS 65
6.1.3 AUTHORITY OF CANNABIS FOR MEDICAL PURPOSES 66
6.1.4 INCREASED USAGE OF CANNABIS SEEDS IN COSMETIC PRODUCTS 67
6.1.5 FUNCTIONAL PROPERTIES OF CANNABIS AND THEIR INCREASED USE IN DIFFERENT INDUSTRIES 67
6.2 RESTRAINTS 68
6.2.1 LONG TERM AND SHORT TERM SIDE EFFECTS RELATED TO THE USE OF CANNABIS AND CANNABIS OVERUSE 68
6.2.2 HIGH COST ASSOCIATED WITH OBTAINING CANNABIS 69
6.2.3 ETHICAL ISSUES RELATED TO THE USE OF MEDICAL CANNABIS 69
6.2.4 COMPLEX REGULATORY STRUCTURE FOR USAGE OF CANNABIS 70
6.3 OPPORTUNITIES 71
6.3.1 NOVEL PRODUCT DEVELOPMENT WITH INCREASING RESEARCH AND DEVELOPMENT (R&D) ACTIVITIES 71
6.3.2 INCREASED MEDICINAL USE OF MEDICAL CANNABIS 71
6.3.3 STRATEGIC INITIATIVES BY MARKET PLAYERS 72
6.4 CHALLENGES 73
6.4.1 SHORTAGE OF SKILLED PROFESSIONAL IN THE INDUSTRY 73
6.4.2 RISE OF THE MARIJUANA BLACK MARKET 73
7 EUROPE MEDICAL CANNABIS MARKET, BY PRODUCT 74
7.1 OVERVIEW 75
7.2 OIL 77
7.3 DRIED MEDICAL CANNABIS 78
7.4 MEDICAL CANNABIS CAPSULES 78
7.5 VAPE PEN 79
7.6 WHOLE FLOWER 80
7.7 CREAMS & MOISTURIZER 80
7.8 GROUND FLOWER 80
7.9 OTHERS 80
8 EUROPE MEDICAL CANNABIS MARKET, BY SOURCE 81
8.1 OVERVIEW 82
8.2 NATURAL 83
8.3 SYNTHETIC 83
9 EUROPE MEDICAL CANNABIS MARKET, BY SPECIES 84
9.1 OVERVIEW 85
9.2 SATIVA 86
9.3 HYBRID 86
9.4 CANNABIS INDICA 86
10 EUROPE MEDICAL CANNABIS MARKET, BY DERIVATIVES 87
10.1 OVERVIEW 88
10.2 CANNABIDIOL (CBD) 89
10.3 (THC)/DELTA-8-TETRAHYDROCANNABINOL 89
10.4 OTHERS 89
11 EUROPE MEDICAL CANNABIS MARKET, BY APPLICATION 90
11.1 OVERVIEW 91
11.2 PAIN MANAGEMENT 92
11.3 ANXIETY 93
11.4 MUSCLE SPASMS 94
11.5 NAUSEA 94
11.6 APPETITE LOSS 95
11.7 CANCER 95
11.8 ARTHRITIS 96
11.9 ALZHEIMER'S DISEASE/MIGRANES 96
11.10 EPILEPSY 97
11.11 DEPRESSION AND SLEEP DISORDERS 97
11.12 MULTIPLE SCLEROSIS 98
11.13 AUTISM 98
11.14 MENTAL HEALTH CONDITIONS 99
11.15 ELEVATE MODD 99
11.16 OTHERS 99
12 EUROPE MEDICAL CANNABIS MARKET, BY ROUTE OF ADMINISTRATION 100
12.1 OVERVIEW 101
12.2 ORAL SOLUTION AND CAPSULES 102
12.3 SMOKING 102
12.4 TOPICALS 102
12.5 VAPORIZERS 102
12.6 OTHERS 102
13 EUROPE MEDICAL CANNABIS MARKET, BY END USER 103
13.1 OVERVIEW 104
13.2 HOMECARE SETTING 105
13.3 HOSPITAL 105
13.4 REHAB CENTERS 105
13.5 PHARMACEUTICAL INDUSTRY 105
13.6 RESEARCH AND DEVELOPMENT CENTERS 105
13.7 OTHERS 105
14 EUROPE MEDICAL CANNABIS MARKET, BY DISTRIBUTION CHANNEL 106
14.1 OVERVIEW 107
14.2 B2C 108
14.3 B2B 108
15 EUROPE MEDICAL CANNABIS MARKET, BY COUNTRY 109
15.1.1 GERMANY 112
15.1.2 U.K. 124
15.1.3 ITALY 136
15.1.4 NETHERLANDS 148
15.1.5 SWITZERLAND 160
15.1.6 FRANCE 172
15.1.7 RUSSIA 184
15.1.8 SPAIN 196
15.1.9 BELGIUM 208
15.1.10 GREECE 220
15.1.11 LUXEMBOURG 232
15.1.12 REST OF EUROPE 244
16 EUROPE MEDICAL CANNABIS MARKET: COMPANY LANDSCAPE 245
16.1 COMPANY SHARE ANALYSIS: EUROPE 245
17 SWOT ANALYSIS 246
18 COMPANY PROFILES 247
18.1 JAZZ PHARMACEUTICALS PLC 247
18.1.1 COMPANY SNAPSHOT 247
18.1.2 REVENUE ANALYSIS 247
18.1.3 PRODUCT PORTFOLIO 248
18.1.4 RECENT DEVELOPMENT 248
18.2 TILRAY 249
18.2.1 COMPANY SNAPSHOT 249
18.2.2 REVENUE ANALYSIS 249
18.2.3 PRODUCT PORTFOLIO 250
18.2.4 RECENT DEVELOPMENTS 250
18.3 AURORA CANNABIS INC. (2021) 251
18.3.1 COMPANY SNAPSHOT 251
18.3.2 REVENUE ANALYSIS 251
18.3.3 PRODUCT PORTFOLIO 252
18.3.4 RECENT DEVELOPMENT 252
18.4 CANOPY GROWTH CORPORATION 253
18.4.1 COMPANY SNAPSHOT 253
18.4.2 REVENUE ANALYSIS 253
18.4.3 PRODUCT PORTFOLIO 254
18.4.4 RECENT DEVELOPMENTS 254
18.5 ECOGEN BIOSCIENCES 255
18.5.1 COMPANY SNAPSHOT 255
18.5.2 PRODUCT PORTFOLIO 255
18.5.3 RECENT DEVELOPMENTS 256
18.6 ALTHEA COMPANY PTY LTD (A SUBSIDIARY OF ALTHEA GROUP HOLDINGS LIMITED) 257
18.6.1 COMPANY SNAPSHOT 257
18.6.2 REVENUE ANALYSIS 257
18.6.3 PRODUCT PORTFOLIO 257
18.6.4 RECENT DEVELOPMENTS 258
18.7 CANNARAY 259
18.7.1 COMPANY SNAPSHOT 259
18.7.2 PRODUCT PORTFOLIO 259
1.5.1 RECENT DEVELOPMENT 259
18.8 GRASS & CO. 260
18.8.1 COMPANY SNAPSHOT 260
18.8.2 PRODUCT PORTFOLIO 260
18.8.3 RECENT DEVELOPMENT 260
18.9 SANITY GROUP GMBH 261
18.9.1 COMPANY SNAPSHOT 261
18.9.2 PRODUCT PORTFOLIO 261
18.9.3 RECENT DEVELOPMENT 261
18.10 PHARMA HEMP (2021) 262
18.10.1 COMPANY SNAPSHOT 262
18.10.2 PRODUCT PORTFOLIO 262
18.10.3 RECENT DEVELOPMENT 262
18.11 MARRICAN INC. 263
18.11.1 COMPANY SNAPSHOT 263
18.11.2 PRODUCT PORTFOLIO 263
18.11.3 RECENT DEVELOPMENT 263
19 QUESTIONNAIRE 264
20 RELATED REPORTS 268